{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.9","upperLimit":"56.7","value":"48.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"}],"units":"Participants"}],"description":"ORR, as determined by central review according to the 2014 Lugano classification, defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurred first.","id":"OG000","title":"Loncastuximab Tesirine"}],"paramType":"NUMBER","populationDescription":"All-treated population - all participants who received at least 1 dose of treatment.","reportingStatus":"POSTED","timeFrame":"Up to 21.5 months","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}